Foetal proglucagon processing in relation to adult appetite control: lessons from a transplantable rat glucagonoma with severe anorexia
- 8 August 2011
- journal article
- review article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 13 (s1) , 60-68
Abstract
We have previously reported severe anorexia abruptly induced in rats 2–3 weeks after they have been transplanted subcutaneously with the glucagonoma MSL‐G‐AN. Vagotomy did not affect the time of onset and severity of anorexia, and the anorectic state resembles hunger with strongly elevated neuropeptide Y (NPY) mRNA levels in the nucleus arcuatus. We now show that circulating levels of bioactive glucagon‐like peptide‐1 (GLP‐1) (7‐36amide) start to increase above control levels exactly at the time of onset of anorexia. At this time‐point, bioactive glucagon as well as total glucagon precursors and GLP‐1 metabolites are already vastly elevated compared to controls. We further show that intravenous administration of very high concentrations of GLP‐1 to hungry schedule‐fed rats causes anorexia in a dose‐dependent manner, which is blocked by the GLP‐1 receptor antagonist exendin (9‐39). GLP‐1 (7‐36amide) has a well‐characterized anorectic effect but also causes taste aversion when administered centrally. The anorectic effect is blocked in rats treated neonatally by monosodium glutamate (MSG). We show that MSG treatment does not prevent the MSL‐G‐AN‐induced anorexia, thereby suggesting a different type of anorectic function. We show a very strong component of taste aversion as anorectic rats, when presented to novel or known alternative food items, will resume normal feeding for 1 day, and then redevelop anorexia. We hypothetize that the anorexia in MSL‐G‐AN tumour‐bearing rats correlates with a foetal processing pattern of proglucagon to both glucagon and GLP‐1 (7‐36amide), and is due to taste aversion. The sudden onset is characterized by a dramatic increase in circulating levels of biologically active GLP‐1 (7‐36amide), suggesting eventual saturation of proteolytic inactivation of its N‐terminus.Keywords
This publication has 56 references indexed in Scilit:
- Gastric Bypass Surgery Enhances Glucagon-Like Peptide 1–Stimulated Postprandial Insulin Secretion in HumansDiabetes, 2011
- The metabolic actions of glucagon revisitedNature Reviews Endocrinology, 2010
- Effect of Chronic Central Administration of Glucagon‐Like Peptide‐1 (7–36) Amide on Food Consumption and Body Weight in Normal and Obese RatsObesity Research, 1998
- Colocalization of Glucagon‐Like Peptide‐1 (GLP‐1) Receptors, Glucose Transporter GLUT‐2, and Glucokinase mRNAs in Rat Hypothalamic Cells: Evidence for a Role of GLP‐1 Receptor Agonists as an Inhibitory Signal for Food and Water IntakeJournal of Neurochemistry, 1996
- A role for glucagon-like peptide-1 in the central regulation of feedingNature, 1996
- Truncated GLP-1 (proglucagon 78?107-amide) inhibits gastric and pancreatic functions in manDigestive Diseases and Sciences, 1993
- Distribution of glucagonlike peptide I (GLP‐I), glucagon, and glicentin in the rat brain: An immunocytochemical studyJournal of Comparative Neurology, 1988
- GLUCAGON-LIKE PEPTIDE-1 7-36: A PHYSIOLOGICAL INCRETIN IN MANThe Lancet, 1987
- Truncated glucagon‐like peptide I, an insulin‐releasing hormone from the distal gutFEBS Letters, 1987
- Cloned cell lines from a transplantable islet cell tumor are heterogeneous and express cholecystokinin in addition to islet hormones.Journal of Cell Biology, 1986